Safety and Efficacy of Routine Bridging Anticoagulation for Subtherapeutic Anticoagulation in Outpatients with a Left Ventricular Assist Device by Shisler, David C et al.
 The VAD Journal: https://doi.org/10.13023/vad.2018.07 Page 1 of 13 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
 
 
 
 
 
 
Peer-Reviewed Original Research 
Safety and Efficacy of Routine Bridging 
Anticoagulation for Subtherapeutic Anticoagulation 
in Outpatients with a Left Ventricular Assist Device 
David C. Shisler1, Gaurang N. Vaidya1, Lori Muncy1, Rajakrishnan 
Vijayakrishnan1, Mark S. Slaughter1, Emma J. Birks1, Dmitry Abramov2 
 *Corresponding author: david.shisler@gmail.com 
1 University of Louisville, Louisville, KY 
2 Loma Linda University, Loma Linda, CA 
  
Abstract 
 
Background 
Anticoagulation with vitamin K antagonists is vital to prevent pump thrombosis in 
patients with left ventricular assist devices (LVADs). However, the safety and 
efficacy of bridging anticoagulation for the routine management of subtherapeutic 
international normalized ratio (INR) in stable outpatients remains poorly 
characterized. 
 
Methods 
 
In this retrospective study, a total of 60 LVAD outpatients had 110 episodes of 
subtherapeutic INR noted on routine testing. 34 of these episodes were managed 
with parenteral bridging anticoagulation and 76 were managed with only an 
adjusted dose of warfarin. The rates of bleeding and thromboembolic adverse 
events following these episodes of subtherapeutic INR were measured to evaluate 
the safety and efficacy of bridging anticoagulation in this population. 
 
Results 
 
Ischemic cerebrovascular events occurred following 2 bridged episodes compared 
to 4 non-bridged episodes (6% vs. 5%, p=0.895). Hemolysis occurred following 1 
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bridged episode compared to 3 non-bridged episodes (3% vs. 4%, p=0.794). 
Bleeding events occurred after 4 bridged episodes compared to 13 non-bridged 
episodes (12% vs. 17%, p=0.474). In a subgroup of patients with either a 
CHA2DS2-VASc score > 3 or a history of atrial fibrillation, thromboembolic events 
occurred only in those who did not receive bridging anticoagulation although this 
result was not statistically significant. 
 
Conclusions 
 
There was no benefit associated with the routine use of bridging anticoagulation in 
a general population of stable LVAD outpatients with subtherapeutic INR. A trend 
towards benefit was seen in a subset of patients with a CHA2DS2-VASc score of > 
3 or a history of atrial fibrillation. 
  
Keywords:   left ventricular assist device, bridging, anticoagulation, bleeding, 
thrombotic complications 
 
Introduction 
 
The use of continuous-flow left ventricular assist devices (LVADs) has resulted in a 
significant improvement in survival and quality of life for patients with advanced 
heart failure.1-3 However, this therapy continues to have a high burden of adverse 
events with frequent hospital readmissions due to bleeding, stroke, infection, and 
pump thrombosis.4 Anticoagulation with vitamin K antagonists is a cornerstone of 
management for LVAD patients to prevent device thrombosis but is complicated by 
a need to maintain a therapeutic international normalized ratio (INR). The 
appropriate management of anticoagulation during periods when the INR is 
subtherapeutic is unclear. There is evidence that the use of parenteral bridging 
anticoagulation in the early post-implant course can help prevent pump 
thrombosis.5 Current guidelines suggest that the use of heparin bridging may be 
considered for patients who need to be off of warfarin for procedures.6 Despite 
frequent use, there is little data regarding bridging anticoagulation in LVAD 
outpatients with subtherapeutic INR, although a recent report suggested an 
increase in adverse events associated with bridging.7 In the current study we 
investigate the efficacy and safety of bridging anticoagulation for the management 
of stable LVAD outpatients with subtherapeutic INR. 
 
Methods 
 
Patient Population 
 
This is a retrospective study of LVAD (HeartMate II or HVAD) patients implanted at 
Jewish Hospital who utilize Alere (Alere Inc., Waltham, MA) home INR monitoring 
services and were noted to have a subtherapeutic INR on routine surveillance. 
Episodes of subtherapeutic INR were selected on the basis of INR measurements 
provided by Alere between April 1, 2015 and May 31, 2017. Alere home monitoring 
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was generally offered to all patients at our program, with enrollment largely 
dependent on insurance coverage and patient preference. The typical INR goal for 
our program was 2.0-3.0, but was often individualized based on either bleeding or 
thrombotic concerns. Routine INR checks were performed weekly for most 
patients, although testing frequency often changed at the discretion of the 
treatment team if an INR was out of range. For inclusion in the study, the patient’s 
INR must have been 0.3 or more below the lower limit of their target INR range. 
This INR cutoff of 0.3 was based on a clinical practice protocol for bridging now 
used at our program based on physician consensus (created independently of this 
research study). We analyzed the data in this way both for research purposes and 
in an attempt to validate our clinical protocol. Subsequent episodes of 
subtherapeutic INR in the same patient were considered as separate episodes if 
they occurred at least 3 months after the preceding episode. Subtherapeutic 
episodes were only included if the patients were otherwise stable in the outpatient 
setting. Episodes in which the INR was subtherapeutic because warfarin was 
purposefully held for procedures or for other reasons were not included. Baseline 
patient characteristics and medical history were obtained via review of medical 
records.  
 
The subtherapeutic episodes were then divided into bridged and non-bridged 
cohorts. Episodes were considered to have been bridged if the patient received at 
least one dose of parenteral anticoagulation (i.e. therapeutic enoxaparin or 
heparin) while the INR was subtherapeutic. The subsequent date at which the 
patient once again achieved therapeutic INR, and bridging was therefore stopped, 
was also noted. The decision to bridge or not bridge each episode was at the 
discretion of the supervising cardiologist at the time of the episode. The usual 
bridging dose was enoxaparin at 1 mg/kg twice daily, up to a maximum of 80 mg 
twice daily, until therapeutic INR was documented. Medical records were then 
reviewed to identify adverse events in the 3 months following the subtherapeutic 
episode.  Relevant adverse events included bleeding events, thromboembolic 
events, and hospitalizations for any cause. A bleeding event was defined as 
hospitalization for clinical signs or symptoms of bleeding including new or 
worsening anemia. Intracranial bleeding was also classified as a bleeding event for 
this study. Thromboembolic events were defined as hemolysis (lactate 
dehydrogenase (LDH) greater than 2.5 times the upper limit of normal) or 
cerebrovascular (transient ischemic attack or ischemic stroke). In addition, the 
patients’ baseline LDH values and as well as the maximum LDH in the 3 months 
following each subtherapeutic episode were recorded. A CHA2DS2-VASc, HAS-
BLED, and ATRIA risk score was also calculated for each subtherapeutic patient 
episode based on the patient data available immediately prior to the episode. This 
research had institutional IRB approval. 
 
Statistical Analysis 
 
IBM SPSS (version 24.0, SPSS Corp, Chicago, IL, USA) was used for statistical 
analysis. Qualitative data is presented as frequencies and quantitative data as 
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mean ± standard deviation. Categorical variables were compared by using Chi-
square test, and continuous variables were compared using Student’s t-test. 
Significance was defined at p-value =<0.05. 
 
Results 
 
Patient and Episode Characteristics 
 
A total of 70 LVAD patients with available Alere INR monitoring data were 
identified, which represented 67% of the 104 LVAD patients at our program during 
the study time. Of those patients, 60 had episodes of subtherapeutic INR meeting 
inclusion criteria. These 60 LVAD patients had 110 episodes of subtherapeutic 
INR that were identified for inclusion in the study. There were 9 patients, 
accounting for 30 subtherapeutic episodes, who had both bridged (11 episodes) 
and non-bridged (19 episodes) events. While the demographics data of these 
patients were included in both the bridged and non-bridged cohorts, removing 
these patients from analysis did not result in any meaningful differences in 
baseline group demographics (data not shown). The average patient was 61 ± 11 
years old and 82% were male (Table 1). HeartMate II LVAD was present in 51% of 
patients and HVAD in 49%.  Of the 110 subtherapeutic episodes, 34 (31%) were 
managed with bridging anticoagulation while the other 76 (69%) were managed 
with an increased dose of warfarin alone. All but one of the bridged episodes were 
treated with enoxaparin, with the remaining episode being treated with 
fondaparinux due to a history of heparin induced thrombocytopenia. The average 
lower target INR for both the bridged and non-bridged episodes was 2.0. The 
average presenting INR for bridged episodes was lower than that for non-bridged 
episodes (1.40 vs. 1.55, p=0.0001). The average number of days spent with 
subtherapeutic INR was 6.1 for bridged episodes versus 9.5 for non-bridged 
episodes (p=0.008) (Table 1).  
 
Outcomes 
 
Within 3 months of the subtherapeutic episode 17 of the patients who received 
bridging anticoagulation were subsequently hospitalized for any reason compared 
to 31 of those who were not bridged (50% vs. 41%, respectively, p=0.368) (Table 
2). Bleeding events occurred in 4 of the bridged patients compared to 13 of the 
non-bridged patients (12% vs. 17%, p=0.474). One of these bleeding events was 
an intracerebral hemorrhage that ultimately resulted in death, which occurred 61 
days after an episode of subtherapeutic INR in a patient that was bridged with 
enoxaparin based on a presenting INR of 1.2. This was the only death noted to 
have occurred within 3 months of a suptherapeutic INR episode during this study. 
Of the remaining bleeding events, 12 were for clinically apparent gastrointestinal 
bleeding, 2 for anemia of unclear etiology, 1 for epistaxis, and 1 for bleeding at the 
driveline exit site. Ischemic cerebrovascular events occurred following 2 bridged 
episodes compared to 4 non-bridged episodes (6% vs. 5%, p=0.895). Hemolysis 
occurred following 1 bridged episode compared to 3 non-bridged episodes (3% vs. 
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4%, p=0.794). LDH level increased by a maximum of 58 after bridged episodes 
versus 105 after non-bridged episodes (p=0.526). We also analyzed the data 
using an INR threshold of 0.5 below target and found no additional meaningful 
differences in outcomes (data not shown). Similar results were also obtained when 
outcomes were limited to exclude patients with a prior history of bleeding or 
thrombotic complications (data not shown). 
 
Table 1 - Baseline Characteristics 
  
Bridged 
(n=34)  
Non-
Bridged 
(n=76) 
p Value 
Number of patients 28 41   
Age 60 ± 12 62 ± 11 0.292 
Male 29 (85) 61 (80) 0.527 
Days since LVAD implantation 530 ± 452 596 ± 384 0.428 
HeartMate II 20 (59) 36 (47) 0.267 
Past medical history     
     Ischemic cardiomyopathy 16 (47) 42 (55) 0.311 
     Major bleeding 9 (26) 28 (37) 0.287 
     Stroke 6 (18) 13 (17) 0.945 
     LVAD associated hemolysis 5 (15) 12 (16) 0.884 
     Atrial fibrillation 12 (35) 37 (49) 0.192 
     Hypertension 28 (82) 61 (80) 0.797 
     Diabetes 14 (41) 34 (45) 0.728 
Baseline laboratory values     
     Creatinine, mg/dL 1.6 ± 1.5 1.3 ± 0.4 0.136 
     GFR, mL/min 66 ± 27 60 ± 20 0.218 
     Hemoglobin, gm/dL 11.7 ± 1.4 11.5 ± 1.9 0.481 
     LDH, u/L 222 ± 77 214 ± 62 0.541 
Risk scores     
     CHA2DS2-VASc score 3.7 ± 1.6 3.9 ± 1.5 0.456 
     HAS-BLED score 3.7 ± 0.9 3.9 ± 1.0 0.674 
     ATRIA score 4.0 ± 1.9 3.6 ± 1.9 0.368 
Subtherapeutic INR episode 
details     
     Presenting INR 1.4 ± 0.2 1.6 ± 0.2 0.0001 
     Minimum goal INR 2.0 ± 0.1 2.0 ± 0.1 0.798 
     Margin from goal INR 0.6 ± 0.2 0.4 ± 0.2 0.0001 
     Number of days 
subtherapeutic 6.1 ± 4.4 9.5 ± 6.9 0.008 
Values are n (%) or mean ± SD. LVAD = left ventricular assist device, 
GFR = glomerular filtration rate, LDH = lactate dehydrogenase, INR = 
international normalized ratio. 
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Table 2 - Three Month Adverse Event Rates 
  
Bridged 
(n=34)  
Non-Bridged 
(n=76) 
p Value 
All-cause hospitalization 17 (50) 31 (41) 0.368 
Bleeding 4 (12) 13 (17) 0.474 
Ischemic cerebrovascular 
event 2 (6) 4 (5) 0.895 
Hemolysis 1 (3) 3 (4) 0.794 
Maximum change in LDH, u/L +58 ± 96 +105 ± 426 0.526 
Values are n (%) or mean ± SD. LDH = lactate dehydrogenase. 
 
Subgroup Analysis 
 
Subtherapeutic INR episodes were divided by CHA2DS2-VASc score between 
those with scores of ≤ 3 (n=47) and those with scores > 3 (n=63). The average 
CHA2DS2-VASc score within the entire cohort was 3.9, 2.4 ± 0.6 within the low 
score group and 5.0 ± 1.1 within the high score group (p=0.0001). Within 3 
months, 4% of those with CHA2DS2-VASc scores ≤ 3 had a subsequent 
thromboembolic event compared to 10% with scores > 3. Among those with 
CHA2DS2-VASc score > 3, there were no thromboembolic events in patients who 
received bridging anticoagulation compared to 6 thromboembolic events in those 
that were not bridged (p=0.133) (Table 3). 
   
Table 3 - Three Month Outcomes by CHA2DS2-VASc Score 
  CHA2DS2-VASc ≤ 3 CHA2DS2-VASc > 3 
  
Bridged 
(n=18)  
Non-
Bridged 
(n=29) 
p 
Value 
Bridged 
(n=16)  
Non-
Bridged 
(n=47) 
p 
Value 
CHA2DS2-VASc score 2.4 ± 0.7 2.4 ± 0.6 0.742 5.1 ± 1.1 4.9 ± 1.0 0.499 
Presenting INR 1.4 ± 0.2 1.6 ± 0.1 0.016 1.4 ± 0.2 1.5 ± 0.2 0.0001 
Days subtherapeutic 5.2 ± 4.6 8.1 ± 6.1 0.09 7.1 ± 4.0 10.4 ± 7.3 0.086 
Adverse event rates         
     All-cause hospitalization 10 (56) 9 (31) 0.096 7 (44) 22 (47) 0.832 
     Bleeding 1 (6) 2 (7) 0.855 3 (19) 11 (23) 0.699 
     Ischemic cerebrovascular 
event 2 (11) 0 0.067 0 4 (9) 0.228 
     Hemolysis 1 (6) 0 0.199 0 3 (6) 0.3 
     Any thromboembolic event 2 (11) 0 0.067 0 6 (13) 0.133 
Maximum change in LDH, u/L 73 ± 120 30 ± 47 0.09 41 152 0.418 
Values are n (%) or mean ± SD. LDH = lactate dehydrogenase, INR = international normalized ratio. 
 
An analysis was also done on those patients with a history of atrial fibrillation 
(n=49) and those without (n=61). Among those patients with atrial fibrillation, no 
thromboembolic events occurred in patients who received bridging anticoagulation 
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compared to 5 thromboembolic events in those who were not bridged (p=0.179) 
(Table 4).  
 
Table 4 - Three Month Outcomes by Atrial Fibrillation Status 
  Atrial Fibrillation No Atrial Fibrillation 
  
Bridged 
(n=12)  
Non-
Bridged 
(n=37) 
p 
Value 
Bridged 
(n=22)  
Non-
Bridged 
(n=39) 
p 
Value 
CHA2DS2-VASc score 3.9 ± 1.4 4.3 ± 1.5 0.442 3.6 ± 1.8 3.6 ± 1.5 0.955 
Presenting INR 1.5 ± 0.2 1.6 ± 0.2 0.041 1.4 ± 0.2 1.5 ± 0.1 0.0001 
Days subtherapeutic 5.4 ± 4.4 10.8 ± 7.4 0.022 6.4 ± 4.4 8.3 ± 6.3 0.216 
Adverse event rates         
     All-cause hospitalization 6 (50) 22 (59) 0.565 11 (50) 9 (23) 0.031 
     Bleeding 1 (8) 11 (30) 0.134 3 (14) 2 (5) 0.245 
     Ischemic cerebrovascular 
event 0 4 (11) 0.235 2 (9) 0 0.056 
     Hemolysis 0 2 (5) 0.411 1 (5) 1 (3) 0.676 
     Any thromboembolic event 0 5 (14) 0.179 2 (9) 1 (3) 0.258 
Maximum change in LDH, u/L 68 ± 84 125 ± 416 0.641 53 ± 103 87 ± 440 0.724 
Values are n (%) or mean ± SD. LDH = lactate dehydrogenase, INR = international normalized ratio. 
 
An additional analysis was done comparing patients with relatively high presenting 
INRs of ≥ 1.5 (n=70) and those with lower INRs of < 1.5 (n=40). All of the 
thromboembolic events noted during the course of this study occurred in patients 
who had a presenting INR  ≥ 1.5, with no thromboembolic events occurring in 
those with INR < 1.5 (p=0.029) (Table 5). Among those with INR > 1.5, there was 
no significant difference in the rate of thromboembolic events between those that 
were bridged and those that were not (14% vs. 11%).  
 
Table 5 - Three Month Outcomes by Presenting INR 
  
INR < 1.5 
(n=40)  
INR ≥ 1.5 
(n=70) 
p Value 
Received bridging 19 (49) 15 (21) 0.003 
Presenting INR 1.3 ± 0.1 1.6 ± 0.1 0.0001 
Minimum goal INR 2.0 ± 0.1 2.0 ± 0.1 0.136 
Days Subtherapeutic 9.1 ± 7.6 8.1 ± 5.7 0.418 
Adverse event rates     
     All-cause hospitalization 18 (46) 30 (42) 0.693 
     Bleeding 8 (21) 9 (13) 0.277 
     Ischemic cerebrovascular event 0 6 (9) 0.062 
     Hemolysis 0 4 (6) 0.131 
     Any thromboembolic event 0 8 (11) 0.029 
Maximum change in LDH, u/L 24 ± 63 127 ± 440 0.151 
Values are n (%) or mean ± SD. INR = international normalized ratio,  
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As an assessment of bleeding risk, a comparison between patients with low versus 
high HAS-BLED scores and low versus high ATRIA scores was performed. Of the 
patients with HAS-BLED scores < 4, 4 of 45 (9%) had a subsequent bleeding 
event compared to 13 of 62 (20%) of those with HAS-BLED score ≥ 4 (p=0.096) 
(Table 6). Of the 33 patients with ATRIA scores < 4, only 1 (3%) had a subsequent 
bleeding event versus 16 of 77 (21%) of those with ATRIA scores ≥ 4 (p=0.018). 
The use of bridging anticoagulation had no significant effect on the rate of bleeding 
events in any of these groups (Data not shown).  
 
Table 6 - Outcomes by Bleeding Risk Score 
  Score < 4 Score ≥ 4 p Value 
HAS-BLED Scores     
Number of patient episodes 45 62   
Average score 2.8 ± 0.4 4.4 ± 0.7 0.0001 
All-cause hospitalization 20 (44) 28 (44) 0.977 
Bleeding 4 (9) 13 (20) 0.096 
Ischemic cerebrovascular 
event 1 (2) 5 (8) 0.199 
Hemolysis 1 (2) 3 (5) 0.487 
      
ATRIA Scores     
Number of patient episodes 33 77   
Average score 1.3 ± 1.0 4.8 ± 1.0 0.0001  
All-cause hospitalization 12 (36) 36 (47) 0.314 
Bleeding 1 (3) 16 (21) 0.018 
Ischemic cerebrovascular 
event 2 (6) 4 (5) 0.855 
Hemolysis 1 (3) 3 (4) 0.824 
Values are n (%) or mean ± SD.  
 
 
Discussion 
 
LVADs have found widespread use as a durable form of heart replacement 
therapy. However, the current generation of continuous flow devices continues to 
be associated with high rates of rehospitalization and adverse events, particularly 
bleeding and thromboembolism. Beginning in 2011 a significant increase in the 
incidence of pump thrombosis was noted, thought to be due in part to the use of 
more relaxed anticoagulation standards after device implant in an effort to reduce 
bleeding complications.8,9 The recent PREVENT trial showed a reduction in pump 
thrombosis with the adoption of stricter guidelines for post-implant management 
including the use of a heparin bridge until a therapeutic INR is obtained.2 However, 
the efficacy and safety of bridging anticoagulation in the outpatient setting for the 
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routine management of subtherapeutic INR remains unclear. Maintaining 
therapeutic INR levels is challenging in the LVAD population with patients typically 
spending only 30-50% of time within therapeutic range and 18-32% of the time 
spent below target.10-12 Several studies have shown that subtherapeutic 
anticoagulation may be a risk factor for thromboembolic complications.13-15 An 
analysis of current practice patterns shows that the routine use of parenteral 
bridging during periods of subtherapeutic INR is common although there is 
significant variability regarding when to initiate bridging.16 Our study found that 
within the overall cohort there was no significant difference in the rates of bleeding 
or thrombotic events between those subtherapeutic episodes managed with 
bridging anticoagulation and those that were not. However, we identified a subset 
of patients with a high CHA2DS2-VASc score or atrial fibrillation who had a trend 
toward benefit from bridging. These results suggest that individualized risk 
assessment may be of value when deciding bridging strategies in patients with 
LVADs.   
 
Several publications have cast doubt on the need for bridging anticoagulation in 
non-LVAD cohorts in the setting of atrial fibrillation and mechanical heart valves. 
The absence of bridging anticoagulation for atrial fibrillation when cessation of 
warfarin was necessary was shown to be non-inferior to enoxaparin bridging and 
decreased the risk of major bleeding in the BRIDGE trial.17 The ORBIT-AF trial 
also showed higher rates of bleeding and adverse events associated with the use 
of peri-procedural bridging for atrial fibrillation.18 A recent study including over 
12,000 episodes of anticoagulation interruption among all patients on warfarin 
therapy found no overall benefit and higher risk of thrombotic events and other 
complications with enoxaparin bridging, and these results held true in the subset of 
patients with mechanical heart valves.19 These authors speculated that the 
counterintuitive increased rate of thrombotic events associated with enoxaparin 
was likely due to underlying factors such that patients at higher baseline risk were 
more likely to be given bridging anticoagulation. The recent 2017 update in the 
AHA/ACC guidelines for management of valvular heart disease reflected these 
results by downgrading their recommendation for peri-procedural bridging 
anticoagulation for mechanical heart valves from class I to class IIa.20  
 
Within the LVAD population, one small study of 18 patients who received 27 
courses of half-dose enoxaparin (0.5 mg/kg every 12 hours) for subtherapeutic 
INR showed no major bleeding or thrombotic events during the treatment period, 
however 3 patients had a subsequent thrombotic event between 1 and 3 months 
after bridging.21 More recently a paper by Bhatia, et al. including 118 LVAD 
patients compared adverse outcomes in those who received bridging 
anticoagulation with enoxaparin at any time during the study period versus those 
who did not receive enoxaparin.7 The authors found that enoxaparin was 
associated with an increased risk of bleeding events as well as a trend towards a 
higher incidence of thromboembolic events in the enoxaparin group. While our 
results similarly show a lack of efficacy in preventing thrombotic events, there are 
several key differences between our study and that by Bhatia. That study utilized a 
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patient-based cohort approach and evaluated outcomes in patients who received 
enoxaparin at any time during the study period, including post-implant and 
periprocedural bridging. In our study we used an episode-based cohort approach 
comparing outcomes following individual episodes of subtherapeutic INR for a 
specific time period of three months in order to capture adverse events that were 
more likely to be related to the episode of subtherapeutic anticoagulation. In 
addition, while the question of post-implant and periprocedural bridging is an 
important one, we included only stable outpatients who were noted to have 
subtherapeutic INR on routine testing in order to address this specific clinical 
scenario. It is also worth noting that Bhatia reported an average bridging duration 
of 18.8 days compared to 6.1 days in our study, which may account for the trend 
toward increased bleeding rates associated with bridging reported in that study.  
Regarding the efficacy of bridging anticoagulation in preventing thromboembolic 
events, our results showed no overall significant difference in the rates of ischemic 
stroke or hemolysis between bridged and non-bridged groups. Higher CHA2DS2-
VASc risk scores have previously been associated with a higher risk of 
thromboembolic events in LVAD patients.22 We hypothesized that CHA2DS2-
VASc scores may identify patients at higher risk of thromboembolic events who 
may therefore derive more benefit from bridging anticoagulation. Our results 
suggest that bridging anticoagulation may be helpful in preventing thromboembolic 
events in patients with scores > 3. Additionally, our analysis suggests that the 
presence of atrial fibrillation may be another factor associated with benefit from the 
use of bridging anticoagulation. However, these findings were not statistically 
significant due to a low power within these subgroups. The presenting INR of the 
subtherapeutic episode did not prove to be beneficial in guiding anticoagulation 
management. 
 
Regarding the safety of bridging anticoagulation, we found no significant difference 
in the rate bleeding events between the bridged and non-bridged groups. Previous 
studies have shown that higher HAS-BLED bleeding risk scores correlate with 
higher bleeding rates in LVAD patients,22,23 and our results show a similar trend. 
However, we found that bleeding event rates were similar regardless of bridging 
anticoagulation and therefore this score was not helpful in guiding management. 
The ATRIA bleeding risk score, which to our knowledge has not previously been 
utilized in the LVAD population, similarly showed higher scores were associated 
with higher bleeding rates, but the score was not beneficial in this cohort to risk 
stratify patients in a way that would alter decision making for bridging.   
This study has multiple limitations. It was a retrospective single-center study with 
all baseline and adverse event data gathered via review of the medical records. 
Decision regarding bridging was at the discretion of the treating heart failure 
cardiologist although there were no significant differences in demographics or 
bleeding and thrombotic risk scores between the groups. Our analysis was based 
on INR measurements reported by the Alere home INR monitoring service and not 
all measurements were verified by repeat laboratory testing. The frequency and 
interval of repeat INR testing after the initial subtherapeutic episode was not 
protocolized and therefore may have been inconsistent. Patient compliance with 
 The VAD Journal: https://doi.org/10.13023/vad.2018.07 Page 11 of 13 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
enoxaparin was not assessed. All adverse events occurring within 3 months of a 
subtherapeutic INR episode were associated with that episode although patients 
may have had additional fluctuations in INR, high or low, during that 3-month 
period. Our patient population was restricted to stable outpatients noted to have 
subtherapeutic INR on routine testing and our results may not be applicable to 
bridging in the immediate post-implant setting or peri-procedural bridging. 
Compared to the INR cutoff used in this study, there may exist a lower INR 
threshold that would show a benefit with bridging. However, our number of patients 
with very low INRs was too small for meaningful analysis. 
 
In conclusion, there was no benefit associated with the routine use of bridging 
anticoagulation in a general population of stable LVAD outpatients with 
subtherapeutic INR. However, bridging anticoagulation may be beneficial in a 
subset of patients who are at higher risk for thromboembolic events as identified 
by a CHA2DS2-VASc score of > 3 or the presence of atrial fibrillation. Bridging 
anticoagulation should be used with caution and requires an individualized 
assessment of a patient’s bleeding and thromboembolic risk with larger 
prospective studies needed to verify these findings.   
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